文献速递浆细胞疾病

TRIM21通过阻止促生存自噬增强多发性骨髓瘤对硼替佐米的敏感性

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy.
PubMed 文献 · Blood Adv · 2023-01-01

本研究探讨E3连接酶TRIM21在多发性骨髓瘤(MM)硼替佐米(bort)耐药中的作用。发现TRIM21低表达是MM复发的因素,敲低TRIM21使MM细胞对bort更耐药,过表达则增加敏感性。机制上TRIM21通过K48泛素化ATG5促进其蛋白酶体降解而影响自噬,体内外实验证实TRIM21可增强bort的抗骨髓瘤效果。

要点

  • TRIM21低表达是MM复发的因素。
  • TRIM21敲低使MM细胞对bort更耐药,过表达增加敏感性。
  • TRIM21通过K48泛素化ATG5促其降解,抑制促生存自噬。

核心结论

  • TRIM21在MM硼替佐米耐药中起关键作用,为新的靶向治疗 approach 提供基础。

研究设计与样本

  • 研究采用MM细胞系及体内外实验,进行蛋白质组和磷酸化蛋白质组分析。

主要发现

  • TRIM21敲低MM细胞在bort处理后诱导促生存自噬。
  • 用3-甲基腺嘌呤处理或敲低ATG5可恢复bort敏感性。
  • TRIM21敲低使ATG5表达增加,过表达使ATG5表达减少。
  • TRIM21通过K48泛素化ATG5促进其蛋白酶体降解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bortezomib (bort) is an effective therapeutic agent for patients with multiple myeloma (MM); however, most patients develop drug resistance. Autophagy, a highly conserved process that recycles cytosol or entire organelles via lysosomal activity, is essential for the survival, homeostasis, and drug resistance in MM. Growing evidence has highlighted that E3 ligase tripartite motif-containing protein 21 (TRIM21) not only interacts with multiple autophagy regulators but also participates in drug resistance in various cancers. However, to date, the direct substrates and additional roles of TRIM21 in MM remain unexplored. In this study, we demonstrated that low TRIM21 expression is a factor for relapse in MM. TRIM21 knockdown (KD) made MM cells more resistant to bort, whereas TRIM21 overexpression (OE) resulted in increased MM sensitivity to bort. Proteomic and phosphoproteomic studies of TRIM21 KD MM cells showed that bort resistance was associated with increased oxidative stress and elevated prosurvival autophagy. Our results showed that TRIM21 KD MM cell lines induced prosurvival autophagy after bort treatment, suppressing autophagy by 3-methyladenine treatment or by the short hairpin RNA of autophagy-related gene 5 (ATG5)-restored-bort sensitivity. Indeed, ATG5 expression was increased and decreased by TRIM21 KD and OE, respectively. TRIM21 affected autophagy by ubiquitinating ATG5 through K48 for proteasomal degradation. Importantly, we confirmed that TRIM21 could potentiate the antimyeloma effect of bort through in vitro and in vivo experiments. Overall, our findings define the key role of TRIM21 in MM bort resistance and provide a foundation for a novel targeted therapeutic approach.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chen J, Cao W, Huang X, et al. TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy. Blood Adv. 2023. PMID: 37083684. doi:10.1182/bloodadvances.2022008241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。